Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Arditya Damarkusuma Added: 1 year ago
In this video, Dr Arditya Damarkusuma (Universitas Gadjah Mada, ID) presents his case report on aorto-ostial lesions, recently published in ICR Journal.This case covers the restenosis of a markedly protruding stent at the right coronary ostium in a 54-year old man, and is unusual in its 10-year longevity. Intravascular ultrasound-guided in-stent restenosis intervention using a wire bumper… View more
Author(s): Marianne Brodmann Added: 1 month ago
CIRSE Congress 2025 - 24-month results show the Biotronik Dynetic-35 cobalt chromium balloon-expandable stent was safe and effective in iliac arteries.Prof Marianne Brodmann (Medical University of Graz, Graz, AT) joins us to discuss 24-month findings from BIONETIC-I (NCT04830228). The prospective, international, multi-center, single-arm study aimed to investigate the safety and effectiveness of… View more
Added: 3 months ago Source:  Radcliffe Cardiology
AUTHOR: Greg GuilloryThe selection of drug-eluting stents (DES) for percutaneous coronary intervention (PCI) involves balancing efficacy against safety. The SORT OUT XI randomised trial aimed to compare a newer-generation biolimus-eluting stent with a contemporary dual-therapy sirolimus-eluting stent in a real-world patient population, providing crucial head-to-head evidence.¹SORT OUT XI was a… View more
Author(s): Jacob Thomsen Lønborg Added: 5 months ago
EuroPCR 25 - 10-year follow-up findings of DANAMI-3-DEFER show a deferred stenting strategy may reduce HF hospitalisation in ST-elevation myocardial infarction (STEMI) patients.We are joined by Dr Jacob Lønborg (Rigshospitalet, Copenhagen, DK) to discuss key findings from the 10-year follow-up of the DANAMI-3-DEFER (NCT01435408) trial. This randomized controlled trial compared deferred stent… View more
Author(s): Robert Yeh Added: 2 years ago
TCT 23 - In this short online interview, we are joined by Dr Robert Yeh (Beth Israel Deaconess Medical Center, US) to discuss the findings of the AGENT IDE trial (NCT04647253), sponsored by Boston Scientific. AGENT IDE is a prospective, 2:1 randomized multicenter trial that aimed to compare the AGENT paclitaxel-coated balloon to plain-old balloon angioplasty (POBA) with a commercially available… View more